207 related articles for article (PubMed ID: 31432695)
21. Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
Tavares M; Chacim S; Mariz JM
Ann Hematol; 2021 Mar; 100(3):837-839. PubMed ID: 33001280
[No Abstract] [Full Text] [Related]
22. Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia.
Thompson DL; Moore DC
J Adv Pract Oncol; 2020 Mar; 11(2):196-200. PubMed ID: 33532119
[TBL] [Abstract][Full Text] [Related]
23. Glasdegib in newly diagnosed acute myeloid leukemia.
Sarkaria SM; Heaney ML
Expert Rev Anticancer Ther; 2021 Jun; 21(6):573-581. PubMed ID: 33593233
[TBL] [Abstract][Full Text] [Related]
24. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
[TBL] [Abstract][Full Text] [Related]
25. Update on glasdegib in acute myeloid leukemia - broadening horizons of Hedgehog pathway inhibitors.
Fersing C; Mathias F
Acta Pharm; 2022 Mar; 72(1):9-34. PubMed ID: 36651529
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).
Sallman DA; Komrokji RS; Sweet KL; Mo Q; McGraw KL; Duong VH; Zhang L; Nardelli LA; Padron E; List AF; Lancet JE
Leuk Res; 2019 Jun; 81():56-61. PubMed ID: 31030089
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
[TBL] [Abstract][Full Text] [Related]
28. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Sekeres MA; Schuster M; Joris M; Krauter J; Maertens J; Breems D; Gyan E; Kovacsovics T; Verma A; Vyas P; Wang ES; Ching K; O'Brien T; Gallo Stampino C; Ma WW; Kudla A; Chan G; Zeidan AM
Ann Hematol; 2022 Aug; 101(8):1689-1701. PubMed ID: 35488900
[TBL] [Abstract][Full Text] [Related]
29. Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient.
Fathi AT
Clin Cancer Res; 2019 Oct; 25(20):6015-6017. PubMed ID: 31324656
[TBL] [Abstract][Full Text] [Related]
30. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
31. Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date.
Iyer SG; Stanchina M; Bradley TJ; Watts J
Cancer Manag Res; 2022; 14():2267-2272. PubMed ID: 35937938
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Macdonald DA; Assouline SE; Brandwein J; Kamel-Reid S; Eisenhauer EA; Couban S; Caplan S; Foo A; Walsh W; Leber B
Leuk Lymphoma; 2013 Apr; 54(4):760-6. PubMed ID: 23061485
[TBL] [Abstract][Full Text] [Related]
33. Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G; DiNardo CD
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
[TBL] [Abstract][Full Text] [Related]
34. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
35. Is the overall survival for older adults with AML finally improving?
Lancet JE
Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
[TBL] [Abstract][Full Text] [Related]
36. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
37. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons.
Tremblay G; Westley T; Cappelleri JC; Arondekar B; Chan G; Bell TJ; Briggs A
Clinicoecon Outcomes Res; 2019; 11():551-565. PubMed ID: 31564931
[TBL] [Abstract][Full Text] [Related]
38. AML: New Drugs but New Challenges.
Burnett A; Stone R
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
[TBL] [Abstract][Full Text] [Related]
39. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA; Montesinos P; Novak J; Wang J; Jeyakumar D; Tomlinson B; Mayer J; Jou E; Robak T; Taussig DC; Dombret H; Merchant A; Shaik N; O'Brien T; Roh W; Liu X; Ma W; DiRienzo CG; Chan G; Cortes JE
Leukemia; 2023 Oct; 37(10):2017-2026. PubMed ID: 37604981
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.
Minami Y; Minami H; Miyamoto T; Yoshimoto G; Kobayashi Y; Munakata W; Onishi Y; Kobayashi M; Ikuta M; Chan G; Woolfson A; Ono C; Shaik MN; Fujii Y; Zheng X; Naoe T
Cancer Sci; 2017 Aug; 108(8):1628-1633. PubMed ID: 28556364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
